

GLAXOSMITHKLINE PLC

Form 6-K/A

January 04, 2016

FORM 6-K/A

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

--

The following announcement replaces the 'Total Voting Rights and Capital' announcement released on 4 January 2016.

The full amended text is shown below.

GlaxoSmithKline plc

Total Voting Rights and Capital

Inconformity with Disclosure and Transparency Rule ('DTR') 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 December 2015 consisted of 5,361,307,647 Ordinary Shares of 25p each, of which 491,515,950 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,869,791,697 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For the purposes of DTR 6.4.2R, the Home State of GlaxoSmithKline plc is the United Kingdom.

V A Whyte
Company Secretary

4 January 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: January 04, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc